Belgium’s largest drugmaker UCB (Euronext: UCB) today revealed that it has received approval from Japan’s Pharmaceuticals and ...

In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

Highlights in myasthenia gravis from AAN 2025 include trials of new therapy inebilizumab, new data on the approved ...

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

Shares of argenx (NASDAQ:ARGX) traded ~14% lower on Thursday after the maker of myasthenia gravis therapy, Vyvgart, missed ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

Dr Nicholas Silvestri reflects on promising new and existing treatment options, reinforcing a personalized approach and ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...